Clinical Trials Browser

Phase 3 × Everolimus × 30 days × Clear all

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell